BR112017019378A2 - análogos de amilina - Google Patents

análogos de amilina

Info

Publication number
BR112017019378A2
BR112017019378A2 BR112017019378-7A BR112017019378A BR112017019378A2 BR 112017019378 A2 BR112017019378 A2 BR 112017019378A2 BR 112017019378 A BR112017019378 A BR 112017019378A BR 112017019378 A2 BR112017019378 A2 BR 112017019378A2
Authority
BR
Brazil
Prior art keywords
disorders
analogs
amylin analogs
amylin
overeating
Prior art date
Application number
BR112017019378-7A
Other languages
English (en)
Inventor
Just Rasmus
Demmer Oliver
Giehm Lise
Sloth Villadsen Jesper
Kofoed Munch Henrik
Skarbaliene Jolanta
Alexandrovna Deryabina Maria
Wolfgang Hamprecht Dieter
Mosolff Mathiesen Jesper
Original Assignee
Zealand Pharma A/S
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017019378(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma A/S, Boehringer Ingelheim International Gmbh filed Critical Zealand Pharma A/S
Publication of BR112017019378A2 publication Critical patent/BR112017019378A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

a presente invenção refere-se a análogos de amilina e ao uso dos mesmos no tratamento ou prevenção de uma variedade de doenças, afecções ou distúrbios, incluindo obesidade, ingestão excessiva de alimentos e doenças metabólicas associadas, como diabetes. os análogos têm boa estabilidade química e física, boa solubilidade e uma longa duração de ação, e são bem adequados ao uso sob a forma de uma formulação líquida.
BR112017019378-7A 2015-03-18 2016-03-17 análogos de amilina BR112017019378A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15159737 2015-03-18
EP15159737.4 2015-03-18
PCT/EP2016/055793 WO2016146739A1 (en) 2015-03-18 2016-03-17 Amylin analogues

Publications (1)

Publication Number Publication Date
BR112017019378A2 true BR112017019378A2 (pt) 2019-02-19

Family

ID=52779493

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019378-7A BR112017019378A2 (pt) 2015-03-18 2016-03-17 análogos de amilina

Country Status (19)

Country Link
US (2) US10766939B2 (pt)
EP (1) EP3271381B1 (pt)
JP (1) JP6769984B2 (pt)
KR (1) KR20170126504A (pt)
CN (1) CN107567459B (pt)
AR (1) AR103954A1 (pt)
AU (1) AU2016232218B2 (pt)
BR (1) BR112017019378A2 (pt)
CA (1) CA2979950A1 (pt)
CL (1) CL2017002256A1 (pt)
CO (1) CO2017008870A2 (pt)
EA (1) EA035791B1 (pt)
IL (1) IL253924A0 (pt)
MX (1) MX2017011182A (pt)
PE (1) PE20180497A1 (pt)
PH (1) PH12017501674A1 (pt)
SG (1) SG11201707286UA (pt)
TW (1) TW201706294A (pt)
WO (1) WO2016146739A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
AU2020384729A1 (en) 2019-11-11 2022-04-14 Boehringer Ingelheim International Gmbh NPY2 receptor agonists
CN116018156A (zh) * 2020-04-20 2023-04-25 I2O治疗公司 使用人类胰淀素类似物多肽对1型糖尿病患者提供卓越的血糖控制
CN116171282A (zh) 2020-08-07 2023-05-26 勃林格殷格翰国际有限公司 可溶npy2受体激动剂
HUE062560T2 (hu) 2020-09-24 2023-11-28 Gubra Aps hAM15-52 analógok javított amilinreceptor (hAMY3R) hatáserõsséggel
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
CN113893349B (zh) * 2021-12-13 2022-07-22 北京大学第三医院（北京大学第三临床医学院） 达格列净及其类似物在制备防治雄性生殖功能障碍的药物中的用途
WO2023227133A1 (zh) * 2022-05-27 2023-11-30 杭州先为达生物科技股份有限公司 人胰淀素类似物、其衍生物及用途
EP4319798A1 (en) * 2022-05-30 2024-02-14 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
DE69232064T2 (de) 1991-11-19 2002-03-28 Amylin Pharmaceuticals Inc Peptide als Amylin-Agonisten und ihre Verwendung
RU2177331C2 (ru) 1993-09-07 2001-12-27 Амилин Фармасьютикалз, Инк. Способы регулирования моторики желудочно-кишечного тракта
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
ATE290014T1 (de) 1996-09-09 2005-03-15 Zealand Pharma As Festphasen-peptidsynthese
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
HUP0200297A3 (en) 1999-03-17 2002-09-30 Novo Nordisk As Method for acylating peptides and the glutaminic acid derivatives as acylating agents
WO2005000222A2 (en) 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
NZ571824A (en) 2004-02-11 2010-04-30 Amylin Pharmaceuticals Inc Amylin family peptides and methods for making and using them
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
DK2370462T3 (da) 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
EP2370461B1 (en) 2008-12-15 2013-10-02 Zealand Pharma A/S Glucagon analogues
KR20110126592A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
BRPI0823378A2 (pt) 2008-12-15 2019-09-24 Zealand Pharma As análogos de glucagon
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
CN102574903B (zh) 2009-07-13 2015-07-08 西兰制药公司 酰化胰高血糖素类似物
CN102639559B (zh) 2009-11-25 2015-04-29 诺沃—诺迪斯克有限公司 用于制备多肽的方法
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
KR20130086343A (ko) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
CA2838884C (en) 2011-06-10 2022-11-29 Novo Nordisk A/S Amylin receptor agonists
WO2013092703A2 (en) 2011-12-23 2013-06-27 Zealand Pharma A/S Glucagon analogues
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
ES2640285T3 (es) * 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) * 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
DK3137494T3 (da) 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
CN106687474A (zh) 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues

Also Published As

Publication number Publication date
TW201706294A (zh) 2017-02-16
US20160272693A1 (en) 2016-09-22
IL253924A0 (en) 2017-10-31
KR20170126504A (ko) 2017-11-17
AR103954A1 (es) 2017-06-14
EP3271381A1 (en) 2018-01-24
JP6769984B2 (ja) 2020-10-14
EA201791617A1 (ru) 2018-02-28
PE20180497A1 (es) 2018-03-09
WO2016146739A1 (en) 2016-09-22
SG11201707286UA (en) 2017-10-30
MX2017011182A (es) 2018-06-06
CN107567459A (zh) 2018-01-09
EA035791B1 (ru) 2020-08-11
CN107567459B (zh) 2021-09-24
AU2016232218A1 (en) 2017-09-21
US20210115104A1 (en) 2021-04-22
CL2017002256A1 (es) 2018-04-02
CA2979950A1 (en) 2016-09-22
AU2016232218B2 (en) 2020-09-10
US10766939B2 (en) 2020-09-08
JP2018510871A (ja) 2018-04-19
PH12017501674A1 (en) 2018-03-12
CO2017008870A2 (es) 2017-11-10
EP3271381B1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
BR112017019378A2 (pt) análogos de amilina
BR112019004534A2 (pt) análogo de amilina, método para a síntese e composição farmacêutica
BR112017024684A2 (pt) compostos coagonistas de glucagon e glp-1
BR112016017045A2 (pt) Derivados de diazepano e usos dos mesmos
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201691619A1 (ru) Конденсированные гетероциклические соединения
BR112016011789A2 (pt) Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos
BR112016026264A2 (pt) sistema e método dos mesmos para otimizar o tempo de inicialização de computadores com múltiplas cpus.
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
BR112016027024A2 (pt) polipeptídeos de ligação específica e seus usos
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112017011198A2 (pt) composição farmacêutica ou nutracêutica com resistência contra a influência do etanol.
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
BR112017025148A2 (pt) composição farmacêutica ou nutracêutica com resistência contra a influência do etanol
BR112018004065A2 (pt) Compostos heterocíclicos, composições farmacêuticas compreendendo os ditos compostos e usos terapêuticos dos mesmos
DK3318251T3 (da) Sammensætning til forebyggelse eller behandling af fedme eller lipidrelateret metabolisk sygdom
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
MA42287A (fr) Traitement de patients atteints de diabète sucré de type 2
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2662 DE 11-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.